Fig. 6From: Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & IIDecreased trend of ferritin level in the treated group within 5 days of starting treatment. Mean reduction of ferritin in treated group was 43% (P < 0.001)Back to article page